biostudies-literatureChang WIntramural NIH HHS3810-20https://www.ebi.ac.uk/biostudies/studies/S-EPMC4970946biostudies-literatureUnknown22(15)<h4>Purpose</h4>We undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers to determine the feasibility of genome-guided precision therapy.<h4>Experimental design</h4>Patients with non-central nervous system solid tumors underwent a combination of whole exome sequencing (WES), whole transcriptome sequencing (WTS), and high-density single-nucleotide polymorphism array analysis of the tumor, with WES of matched germline DNA. Clinically actionable alterations were identified as a reportable germline mutation, a diagnosis change, or a somatic event (including a single nucleotide variant, an indel, an amplification, a deletion, or a fusion gene), which could be targeted with drugs in existing clinical trials or with FDA-aClinical cancer research : an official journal of the American Association for Cancer ResearchMultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.PMC4970946ZIA BC010998ZIA BC011002Gryder BWen XPatidar RWidemann BCLin JCBrohl ASBadgett TCShivaprasad NMiettinen MShern JFZhang SChang WHartman KRKaplan RNSong YKKhan JCalzone KAYohe MEWei JSTrahair TNMerchant MSSindiri SLeague-Pascual JCfalseMultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.<h4>Purpose</h4>We undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers to determine the feasibility of genome-guided precision therapy.<h4>Experimental design</h4>Patients with non-central nervous system solid tumors underwent a combination of whole exome sequencing (WES), whole transcriptome sequencing (WTS), and high-density single-nucleotide polymorphism array analysis of the tumor, with WES of matched germline DNA. Clinically actionable alterations were identified as a reportable germline mutation, a diagnosis change, or a somatic event (including a single nucleotide variant, an indel, an amplification, a deletion, or a fusion gene), which could be targeted with drugs in existing clinical trials or with FDA-a2016-01-01T00:00:00Z2016 Aug2026-05-04T10:35:48.769Z2019-03-27T02:19:45ZS-EPMC49709462699414510.1158/1078-0432.ccr-15-271710.1158/1078-0432.CCR-15-2717